Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

References

• Department for Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the DHHS Panel on antiretroviral guidelines for adults and adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). http://aidsinfo.nih.gov/guidelines on 5/11/2015. Last Updated 08 April 2015.
   Google Scholar
• Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®). Drugs. 2010;70:2315–2338.10.2165/11203800-000000000-00000
   PubMed Web of Science ®Google Scholar
• Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? Curr Med Res Opin. 2013;30:89–97.
   PubMed Web of Science ®Google Scholar
• Hanna DB, Hessol NA, Golub ET, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr. 2014;65:587–596.10.1097/QAI.0000000000000082
   PubMed Web of Science ®Google Scholar
• Shaw J-P, Sueoka CM, Oliyai R, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res. 1997;14:1824–1829.10.1023/A:1012108719462
   PubMed Web of Science ®Google Scholar
• Arimilli M, Kim C, Bischofberger N. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antivir Chem Chemother. 1997;8:557–564.
   Web of Science ®Google Scholar
• Naesens L, Bischofberger N, Augustijns P, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9(2-phosphonylmethoxypropyl) adenine in mice. Antimicrob Agents Chemother. 1998;42:1568–1573.
   PubMed Web of Science ®Google Scholar
• Suo Z, Johnson KA. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl) adenine. J Biol Chem. 1998;273:27250–27258.10.1074/jbc.273.42.27250
   PubMed Web of Science ®Google Scholar
• Robbins BL, Greenhaw JJ, Connelly MC, Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother. 1995;39:2304–2308.10.1128/AAC.39.10.2304
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest. 2011;91:852–858.10.1038/labinvest.2011.48
   PubMed Web of Science ®Google Scholar
• Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010;9:545–559.10.1517/14740331003627458
   PubMed Web of Science ®Google Scholar
• Lee WA, He G-X, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898–1906.10.1128/AAC.49.5.1898-1906.2005
   PubMed Web of Science ®Google Scholar
• Eisenberg EJ, He G-X, Lee WA. Metabolism Of Gs-7340, A novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids. 2001;20:1091–1098.10.1081/NCN-100002496
   PubMed Web of Science ®Google Scholar
• Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63:449–455.10.1097/QAI.0b013e3182965d45
   PubMed Web of Science ®Google Scholar
• Callebaut C, Stepan G, Tian Y, Miller MD. In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to tenofovir disoproxil fumarate. Antimicrob Agents Chemother 2015;59:5909–5916.
   PubMed Web of Science ®Google Scholar
• Reich M, Spindler KD, Burret M, Kalbacher H, Boehm BO, Burster T. Cathepsin A is expressed in primary human antigen-presenting cells. Immunol. Lett. 2010;128:143–147.10.1016/j.imlet.2009.11.010
   PubMed Web of Science ®Google Scholar
• Birkus G, Kutty N, He GX, et al. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol. 2008;74:92–100.10.1124/mol.108.045526
   PubMed Web of Science ®Google Scholar
• Murakami E, Wang T, Park Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 2015;59:3563–3569.10.1128/AAC.00128-15
   PubMed Web of Science ®Google Scholar
• Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67:52–58.10.1097/QAI.0000000000000225
   PubMedGoogle Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606–2615.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Zolopa A, Squires K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014;69:1362–1369.10.1093/jac/dkt532
   PubMed Web of Science ®Google Scholar
• Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920–928.10.1128/AAC.44.4.920-928.2000
   PubMed Web of Science ®Google Scholar
• Varghese V, Liu TF, Rhee SY, et al. HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses. 2010;26:1323–1326.10.1089/aid.2010.0123
   PubMed Web of Science ®Google Scholar
• Wensing AM, Calvez V, Gunthard HF, et al. 2014 update of the drug resistance mutations in HIV-1. Topics in antiviral med. 2014;22:642–650.
   PubMedGoogle Scholar
• Yang X, Charlebois P, Gnerre S, et al. De novo assembly of highly diverse viral populations. BMC Genomics. 2012;13:475.10.1186/1471-2164-13-475
   PubMed Web of Science ®Google Scholar
• Lee WP, Stromberg MP, Ward A, Stewart C, Garrison EP, Marth GT. MOSAIK: a hash-based algorithm for accurate next-generation sequencing short-read mapping. PLoS ONE. 2014;9:e90581.10.1371/journal.pone.0090581
   PubMed Web of Science ®Google Scholar
• Hertogs K, Bloor S, De Vroey V, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184 V. Antimicrob Agents Chemother. 2000;44:568–573.10.1128/AAC.44.3.568-573.2000
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Nurutdinova D, Grubb JR, et al. Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28:259–264.10.1089/aid.2011.0022
   PubMed Web of Science ®Google Scholar
• Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV Type 1–infected patients after receipt of first‐line highly active antiretroviral therapy: a systematic review of clinical trials. Clinical Infectious Diseases. 2008;47:712–722.10.1086/592125
   PubMed Web of Science ®Google Scholar
• Messou E, Chaix ML, Gabillard D, et al. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Cote d’Ivoire, West Africa. J Acquir Immune Defic Syndr 2013;64:211–219.10.1097/QAI.0b013e3182a009e4
   PubMed Web of Science ®Google Scholar
• White KL, Raffi F, Miller MD. Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients. Viruses. 2014;6:2858–2879.10.3390/v6072858
   PubMed Web of Science ®Google Scholar
• Margot NA, Johnson A, Miller MD, Callebaut C. Characterization of HIV-1 resistance to tenofovir alafenamide In Vitro. Antimicrob Agents Chemother. 2015;59:5917–5924.10.1128/AAC.01151-15
   PubMed Web of Science ®Google Scholar